Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Major Shareholder Sells 22,996 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 22,996 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $30.03, for a total value of $690,569.88. Following the completion of the sale, the insider now directly owns 6,278,504 shares in the company, valued at $188,543,475.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.06, for a total value of $2,551,522.86.
  • On Wednesday, January 3rd, Portage Biotech Inc. sold 35,650 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $28.61, for a total value of $1,019,946.50.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) opened at $26.57 on Wednesday. Biohaven Pharmaceutical Holding Co Ltd has a 12 month low of $17.00 and a 12 month high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its earnings results on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.03. analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 EPS for the current year.

A number of large investors have recently bought and sold shares of the business. VHCP Management II LLC purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at $60,826,000. Eagle Asset Management Inc. purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at $32,635,000. Janus Henderson Group PLC purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at $25,751,000. JPMorgan Chase & Co. purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at $18,173,000. Finally, Stifel Financial Corp purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at $15,525,000. Institutional investors own 47.76% of the company’s stock.

A number of analysts have recently issued reports on BHVN shares. Canaccord Genuity assumed coverage on Biohaven Pharmaceutical in a research note on Friday, December 15th. They issued a “buy” rating and a $30.00 price target on the stock. Morgan Stanley boosted their price objective on Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, September 25th. Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. BidaskClub lowered Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Finally, Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Biohaven Pharmaceutical has an average rating of “Buy” and an average target price of $36.14.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Major Shareholder Sells 22,996 Shares of Stock” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/biohaven-pharmaceutical-holding-co-ltd-bhvn-major-shareholder-portage-biotech-inc-sells-22996-shares-of-stock/1821831.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.